[On the excretion of azlocillin with bronchial secretion in children (author's transl)].
This pharmacokinetic study involved school children who were treated with 6-[(R)-2-(2-oxo-imidazolidine-1-carboxamido)-2-phenyl-acetamido]-penicillanic acid sodium walt (azlocillin, Securopen) at doses of 50 mg/kg bodyweight or 75 mg/kg body weight i.v. Kinetics of the first order were found for the concentrations measured at the same time, being proportionate to the administered dose, while there was no dose dependence for the relative distribution volume. The elimination half-life was about 55 min. In 25 children of different age who had to undergo bronchoscopy for diagnositic and therapeutic reasons, the azlocillin concentrations in the bronchial secretions were measured 1 h and 4 h after the administration of 75 mg/kg quantity of bronchial secretion was obtained, azlocillin concentrations of 30 - 240 microgram/g were found. Measurements of azlocillin concentration in the bronchial secretion and in the serum, which were made at the same time, did not show any correlation.
D000293:Adolescent; D000375:Aging; D001390:Azlocillin; D001980:Bronchi / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D010406:Penicillins / Q000378:metabolism* / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000188:drug therapy
D010406:Penicillins; D001390:Azlocillin
Zur Frage der Ausscheidung von Azlocillin in das Bronchialsekret im Kindesalter.